Fantasy Drugs Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
as on 08-07-2024
- Paid Up Capital ₹ 1.94 Cr
as on 08-07-2024
- Company Age 26 Year, 9 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 11.01 Cr
as on 08-07-2024
- Revenue 49.19%
(FY 2021)
- Profit 107.16%
(FY 2021)
- Ebitda 54.53%
(FY 2021)
- Net Worth 7.01%
(FY 2021)
- Total Assets 6.01%
(FY 2021)
About Fantasy Drugs
The Corporate was formerly known as Shaktishree Industrial Products Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 1.94 Cr.
The company currently has active open charges totaling ₹11.01 Cr.
Vidya Sagar and Uma Shankar serve as directors at the Company.
- CIN/LLPIN
U00893BR1998PTC008367
- Company No.
008367
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Feb 1998
- Date of AGM
29 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Company Details
- Location
Patna, Bihar, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Fantasy Drugs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vidya Sagar  | Director | 03-Sep-2012 | Current |
| Uma Shankar | Director | 03-Sep-2012 | Current |
Financial Performance and Corporate Structure Insights of Fantasy Drugs.
Fantasy Drugs Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 49.19% increase. The company also saw a substantial improvement in profitability, with a 107.16% increase in profit. The company's net worth moved up by a moderate rise of 7.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Fantasy Drugs?
In 2021, Fantasy Drugs had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Console Lifesciences Private LimitedActive 12 years 4 monthsVidya Sagar and Uma Shankar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 09 Feb 2024 | ₹1.00 Cr | Open |
Canara Bank Creation Date: 09 Feb 2024 | ₹1.05 Cr | Open |
Canara Bank Creation Date: 28 Jul 2020 | ₹0.58 M | Open |
How Many Employees Work at Fantasy Drugs?
Fantasy Drugs has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Fantasy Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fantasy Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
